Unidad Monitorización Fármacos, Laboratorio Central, Hospital Clínico Universitario, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain.
Scand J Clin Lab Invest. 2012 Apr;72(2):180-3. doi: 10.3109/00365513.2011.646300. Epub 2012 Jan 17.
There is significant immunoassay cross-reactivity between everolimus and sirolimus, and their routine determination using a common method may reduce the reagent costs.
In 122 blood samples from kidney (n = 30) and liver (n = 92) transplant recipients, everolimus concentrations were determined using the Abbott IMx® microparticle enzyme immunoassay (MEIA) as previously described, and the Abbott sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® system.
A high correlation coefficient (r = 0.981, p < 0.001) and a linear regression MEIA = 0.73CMIA + 0.55, with an acceptable standard error of the estimate (ma68 = 0.32 ng/mL), were obtained, indicating the transferability of the results produced by both immunoassays.
The newly-developed sirolimus CMIA assay on the Architect® platform may be a valid alternative to other immunoassays for the routine therapeutic monitoring of everolimus.
依维莫司和西罗莫司之间存在显著的免疫测定交叉反应，因此使用通用方法常规测定这两种药物的浓度可以降低试剂成本。
在 122 例来自肾（n=30）和肝（n=92）移植受者的血样中，使用Abbott IMx®微粒酶免疫分析法（MEIA）如前所述来测定依维莫司浓度，并使用Architect-i1000®系统上的 Abbott 西罗莫司化学发光磁微粒免疫分析法（CMIA）来测定西罗莫司浓度。
得到了一个高相关系数（r=0.981，p<0.001）和一个线性回归 MEIA=0.73CMIA+0.55，具有可接受的估计标准误差（ma68=0.32ng/mL），这表明两种免疫分析法的结果具有可转移性。
Architect®平台上新开发的西罗莫司 CMIA 检测法可能是常规监测依维莫司治疗药物浓度的其他免疫分析法的有效替代方法。
